Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor

Journal of Biological Chemistry

Volumn 289, Issue 12, 2014, Pages 8706-8719

  Gupta, Shashi ^a   Hirota, Masao ^b   Waugh, Sheela M ^a   Murakami, Ikuo ^b   Suzuki, Tomoki ^b   Muraguchi, Masahiro ^b   Shibamori, Masafumi ^b   Ishikawa, Yuichi ^b   Jarvis, Thale C ^a   Carter, Jeffrey D ^a   Zhang, Chi ^a   Gawande, Bharat ^a   Vrkljan, Michael ^a   Janjic, Nebojsa ^a   Schneider, Daniel J ^a  

^a SomaLogic Inc   (United States)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; BODY FLUIDS; CELL SIGNALING; DISEASES; SIGNALING;

CHEMICALLY MODIFIED; HIGH AFFINITY BINDING; INFLAMMATORY DISEASE; INFLAMMATORY RESPONSE; INHIBITION ACTIVITY; INHIBITION PROPERTY; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENTS; UNIQUE SEQUENCE;

IMMUNOLOGY;

5 (N BENZYLCARBOXAMIDE) 2' DEOXYURIDINE; 5 [N (1 NAPHTHYLMETHYL)CARBOXAMIDE] 2' DEOXYURIDINE; ANTIINFLAMMATORY AGENT; APTAMER; ENDONUCLEASE; INTERLEUKIN 6; INTERLEUKIN 6 INHIBITOR; INTERLEUKIN 6 RECEPTOR; TOCILIZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CHEMICAL MODIFICATION; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; HYDROPHOBICITY; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

APTAMERS; CELL SIGNALING; DRUG DISCOVERY; INTERLEUKIN; MOLECULAR EVOLUTION; NUCLEASE STABILITY; NUCLEIC ACID CHEMISTRY; PROTEIN-DNA INTERACTION; SELEX; SOMAMER;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; CHO CELLS; CRICETULUS; DRUG DISCOVERY; HUMANS; INTERLEUKIN-6; MACACA FASCICULARIS; MICE; MOLECULAR SEQUENCE DATA; RATS; RECEPTORS, INTERLEUKIN-6; SELEX APTAMER TECHNIQUE; SERUM;

EID: 84896996881     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.532580     Document Type: Article

References (51)

1. Heinrich, P. C., Behrmann, I., Müller-Newen, G., Schaper, F., and Graeve, L. (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334, 297-314 (Pubitemid 28448572)
2. Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S., Nakajima, K., Koyama, K., Iwamatsu, A., Tsunasawa, S., Sakiyama, F., Matsui, H., Takahara, Y., Taniguchi, T., and Kishimoto, T. (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324, 73-76 (Pubitemid 16008419)
3. Somers, W., Stahl, M., and Seehra, J. S. (1997) 1.9 Å crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. EMBO J. 16, 989-997 (Pubitemid 27113178)
4. Kishimoto, T. (2005) Interleukin-6: from basic science to medicine-40 years in immunology. Annu. Rev. Immunol. 23, 1-21
5. Scheller, J., Chalaris, A., Schmidt-Arras, D., and Rose-John, S. (2011) The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 1813, 878-888
6. Honda, M., Yamamoto, S., Cheng, M., Yasukawa, K., Suzuki, H., Saito, T., Osugi, Y., Tokunaga, T., and Kishimoto, T. (1992) Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J. Immunol. 148, 2175-2180
7. Novick, D., Engelmann, H., Wallach, D., and Rubinstein, M. (1989) Soluble cytokine receptors are present in normal human urine. J. Exp. Med. 170, 1409-1414 (Pubitemid 19250702)
8. Waetzig, G. H., and Rose-John, S. (2012) Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin. Ther. Targets 16, 225-236
9. Rose-John, S. (2012) IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 8, 1237-1247
10. Guo, Y., Xu, F., Lu, T., Duan, Z., and Zhang, Z. (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. 38, 904-910
11. Waage, A., Brandtzaeg, P., Halstensen, A., Kierulf, P., and Espevik, T. (1989) The complex pattern of cytokines in serum from patients with meningococcal septic shock. J. Exp. Med. 169, 333-338
12. Kopf, M., Bachmann, M. F., and Marsland, B. J. (2010) Averting inflammation by targeting the cytokine environment. Nat. Rev. Drug Discov. 9, 703-718
13. Dayer, J. M., and Choy, E. (2010) Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology 49, 15-24
14. Tanaka, T., Narazaki, M., and Kishimoto, T. (2012) Therapeutic targeting of the interleukin-6 receptor. Annu. Rev. Pharmacol. Toxicol. 52, 199-219
15. Nishimoto, N., Kishimoto, T., and Yoshizaki, K. (2000) Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann. Rheum. Dis. 59, suppl. 1:i21-27
16. Smolen, J. S., and Maini, R. N. (2006) Interleukin-6: a new therapeutic target. Arthritis Res. Ther. 8, S5
17. Tanaka, T., and Kishimoto, T. (2012) Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int. J. Biol. Sci. 8, 1227-1236
18. Ellington, A. D., and Szostak, J. W. (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822
19. Tuerk, C., and Gold, L. (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510
20. Gupta, S., Thirstrup, D., Jarvis, T. C., Schneider, D. J., Wilcox, S. K., Carter, J., Zhang, C., Gelinas, A., Weiss, A., Janjic, N., and Baird, G. S. (2011) Rapid histochemistry using slow off-rate modified aptamers with anionic competition. Appl. Immunohistochem. Mol. Morphol. 19, 273-278
21. Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., Flather, D., Forbes, A., Foreman, T., Fowler, C., Gawande, B., Goss, M., Gunn, M., Gupta, S., Halladay, D., Heil, J., Heilig, J., Hicke, B., Husar, G., Janjic, N., Jarvis, T., Jennings, S., Katilius, E., Keeney, T. R., Kim, N., Koch, T. H., Kraemer, S., Kroiss, L., Le, N., Levine, D., Lindsey, W., Lollo, B., Mayfield, W., Mehan, M., Mehler, R., Nelson, S. K., Nelson, M., Nieuwlandt, D., Nikrad, M., Ochsner, U., Ostroff, R. M., Otis, M., Parker, T., Pietrasiewicz, S., Resnicow, D. I., Rohloff, J., Sanders, G., Sattin, S., Schneider, D., Singer, B., Stanton, M., Sterkel, A., Stewart, A., Stratford, S., Vaught, J. D., Vrkljan, M., Walker, J. J., Watrobka, M., Waugh, S., Weiss, A., Wilcox, S. K., Wolfson, A., Wolk, S. K., Zhang, C., and Zichi, D. (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PloS one 5, e15004
22. Mascini, M., and Tombelli, S. (2008) Biosensors for biomarkers in medical diagnostics. Biomarkers 13, 637-657
23. Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., and Janjić, N. (1998) 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273, 20556-20567 (Pubitemid 28377626)
24. Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Jr., Feinsod, M., Guyer, D. R., and VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004) Pegaptanib for neovascular age-related macular degeneration. New Engl. J. Med. 351, 2805-2816 (Pubitemid 40051904)
25. Chan, M. Y., Rusconi, C. P., Alexander, J. H., Tonkens, R. M., Harrington, R. A., and Becker, R. C. (2008) A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J. Thromb. Haemost. 6, 789-796 (Pubitemid 351524539)
26. Boyer, D. (2013) A phase 2b study of Fovista™, a platelet derived growth factor (PDGF) inhibitor in combination with a vascular endothelial growth factor (VEGF) inhibitor for neovascular age-related macular degeneration (AMD). Investi. Ophthalmol. Visual Sci. 54, E-Abstract 2175
27. Cousins, S. W., and Ophthotech Study group (2010) Targeting complement factor 5 in combination with vascular endothelial growth factor (VEGF inhibition for neovascular age-related macular degeneration (AMD): results of a phase 1 study). Invest. Ophthalmol. Visual Sci. 51, E-Abstract 1251
28. Keefe, A. D., Pai, S., and Ellington, A. (2010) Aptamers as therapeutics. Nat. Rev. Drug Discov. 9, 537-550
29. Bouchard, P. R., Hutabarat, R. M., and Thompson, K. M. (2010) Discovery and development of therapeutic aptamers. Annu. Rev. Pharmacol. Toxicol. 50, 237-257
30. Vaught, J. D., Bock, C., Carter, J., Fitzwater, T., Otis, M., Schneider, D., Rolando, J., Waugh, S., Wilcox, S. K., and Eaton, B. E. (2010) Expanding the chemistry of DNA for in vitro selection. J. Am. Chem. Soc. 132, 4141-4151
31. Beaucage, S., and Caruthers, M. (1981) Deoxynucleoside phosphoramidites - A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22, 1859-1862
32. Davies, D. R., Gelinas, A. D., Zhang, C., Rohloff, J. C., Carter, J. D., O'Connell, D., Waugh, S. M., Wolk, S. K., Mayfield, W. S., Burgin, A. B., Edwards, T. E., Stewart, L. J., Gold, L., Janjic, N., and Jarvis, T. C. (2012) Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets. Proc. Natl. Acad. Sci. U.S.A. 109, 19971-19976
33. Aaronson, D. S., and Horvath, C. M. (2002) A road map for those who don't know JAK-STAT. Science 296, 1653-1655 (Pubitemid 34579157)
34. Beigelman, L., McSwiggen, J. A., Draper, K. G., Gonzalez, C., Jensen, K., Karpeisky, A. M., Modak, A. S., Matulic-Adamic, J., DiRenzo, A. B., Haeberli, P., Sweedlere, D., Tracz, D., Grimm, S., Wincott, F., Thackray, V., and Usman, N. (1995) Chemical modification of hammerhead ribozymes. J. Biol. Chem. 270, 25702-25708
35. Kawaguchi, T., Asakawa, H., Tashiro, Y., Juni, K., and Sueishi, T. (1995) Stability, specific binding activity, and plasma concentration in mice of an oligodeoxynucleotide modified at 5′-terminal with poly(ethylene glycol). Biol. Pharm. Bull. 18, 474-476
36. Watson, S. R., Chang, Y. F., O'Connell, D., Weigand, L., Ringquist, S., and Parma, D. H. (2000) Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo. Antisense Nucleic Acid Drug Dev. 10, 63-75 (Pubitemid 30255590)
37. Burnett, J. C., and Rossi, J. J. (2012) RNA-based therapeutics: current progress and future prospects. Chem. Biol. 19, 60-71
38. Eaton, B. E., Gold, L., Hicke, B. J., Janjić, N., Jucker, F. M., Sebesta, D. P., Tarasow, T. M., Willis, M. C., and Zichi, D. A. (1997) Post-SELEX combinatorial optimization of aptamers. Bioorg. Med. Chem. 5, 1087-1096 (Pubitemid 27264835)
39. Green, L. S., Jellinek, D., Bell, C., Beebe, L. A., Feistner, B. D., Gill, S. C., Jucker, F. M., and Janjić, N. (1995) Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem. Biol. 2, 683-695
40. Jellinek, D., Green, L. S., Bell, C., and Janjić, N. (1994) Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. Biochemistry 33, 10450-10456 (Pubitemid 24281813)
41. Guschlbauer, W., and Jankowski, K. (1980) Nucleoside conformation is determined by the electronegativity of the sugar substituent. Nucleic Acids Res. 8, 1421-1433
42. Griffin, L. C., Tidmarsh, G. F., Bock, L. C., Toole, J. J., and Leung, L. L. (1993) In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 81, 3271-3276 (Pubitemid 23172909)
43. Ara, T., and Declerck, Y. A. (2010) Interleukin-6 in bone metastasis and cancer progression. Eur. J. Cancer 46, 1223-1231
44. Kishimoto, T. (2010) IL-6: from its discovery to clinical applications. Int. Immunol. 22, 347-352
45. Jones, S. A., Scheller, J., and Rose-John, S. (2011) Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121, 3375-3383
46. Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., and Kakehi, T. (2008) Mechanisms and pathologic significances increase in serum in-terleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112, 3959-3964
47. Singh, J. A., Beg, S., and Lopez-Olivo, M. A. (2011) Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J. Rheumatol. 38, 10-20
48. Weinblatt, M., Mease, P., Mysler, E., Takeuchi, T., Drescher, E., Berman, A., Zilberstein, M., Xing, J., and Emery, P. (2013) A phase IIb study of the efficacy and safety of subcutaneous Clazakizumab (anti-IL-6 monoclonal antibody) with methotrexate in adults with moderate-to-severe active rheumatoid arthritis and an inadequate response to methotrexate. Arthritis and Rheumatism 65(10) Supplement, Abstract #1735, S735
49. Zhao, Q., Pang, J., Shuster, D., Hung, C., Baglino, S., Dodge, R., Sun, H., Trigona, W. and Salter-Cid, L. (2013) Anti-IL-6 antibody Clazakizumab is more potent than Tocilizumab in blocking in vitro and ex vivo IL-6-induced functions. Arthritis and Rheumatism 65(10) Supplement, Abstract # 2385, S1020
50. Gelinas, A. D., Davies, D. R., Edwards, T. E., Rohloff, J. C., Carter, J. D., Zhang, C., Gupta, S., Ishikawa, Y., Hirota, M., Nakaishi, Y., Jarvis, T. C., and Janjic, N. (January 12, 2014) Crystal structure of interleukin-6 in complex with a modified nucleic acid ligand. J. Biol. Chem. 289, 8720-8734
51. Meyer, C., Berg, K., Eydeler-Haeder, K., Lorenzen, I., Grötzinger, J., Rose-John, S., and Hahn, U. (2014) Stabilized interleukin-6 receptor binding RNA aptamers. RNA Biol. 11, 1-9